Medical Marijuana: A Challenge to Traditional Pain Relief?
Published in Pharmaceutical Executive November 2017
Medical use of marijuana for a broad range of conditions is expanding rapidly in the US, as legalization gathers pace and investors flock to a booming market. A January 2017 report for the National Academies of Sciences, Engineering and Medicine (NASEM) found substantial or conclusive evidence of marijuana’s therapeutic benefit in chronic pain, multiple sclerosis and chemotherapy-induced nausea and vomiting. Other, more tentative US state-approved indications include diabetes, glaucoma, epilepsy, migraine, post-traumatic stress disorder, hepatitis C, Crohn’s disease, Parkinson’s diseaseand Tourette syndrome.
Living with NASH: An Unexpected Diagnosis
Published in eyeforpharma November 2017 by Mariel Metcalfe
With no current licensed treatments and more than 20 compounds in phase II and III, the liver disease non-alcoholic steatohepatitis (NASH) represents a huge opportunity for pharma companies – if they understand patient needs. As our waistlines thicken and our activity levels decrease, another chronic illness threatens to disturb our comfortable lifestyles. And, because it’s relatively unknown, diagnosis comes as a shock to patients, who usually associate liver disease with heavy consumption of alcohol.
Innovation, sustainability and prosperity: Japan’s healthcare vision for the future
Published in eyeforpharma October 2017 by Callum McCulloch and Marc Yates
The vision for Japan 2035; A healthcare system that delivers unrivalled health outcomes, providing secure and responsive care for all members of society, sustainable, and contributing to prosperity in the nation and around the world. But how achievable is this ideal, and how do they plan to make it happen? In 2015 the Japanese government appointed an advisory panel of young experts to lay out its vision of healthcare in the country for 2035. It will require a paradigm shift from the current healthcare system in many aspects; moving from quantity to quality of care, shifting the focus onto value rather than inputs, on care rather than cure, autonomy rather than regulation, and national integration rather than fragmentation.
Deep Dive - MINT: opportunities in ‘frontier’ markets?
Published in Pharmaphorum’s Deep Dive magazine October 2017
According to British economist Jim O’Neill, MINT is the new BRIC. What is MINT? An acronym he coined for the ‘frontier’ markets of Mexico, Indonesia, Nigeria and Turkey. These are the countries he believes are poised for strong economic growth, like the emerging markets of BRIC (Brazil, Russia, India and China) before them. What are the prospects for pharma in MINT? Research Partnership’s Rachel Howard and Sue Rees investigate the pros and cons.
Ageing Asia: What does the future hold?
Published in eyeforpharma September 2017 by Heli Brahmbhatt and Marc Yates
Over the last 30 years, Asia’s economic growth has resulted in improved education and healthcare across a broad base of the population, contributing to declining fertility and increasing life expectancy. However, in turn, such changing demographic features are set to have profound repercussions on the continent’s socio-economic and healthcare set-up in the coming decades.